How to Move Forward After a Thumbs Down from FDA: Interview with Kevin Sidow, Former CEO and President of Moximed

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded08 Feb 2020

Publisherfeeds.transistor.fm ↗

Handlerec:13866385

Show notes

In late 2016, I was able to sit down with Kevin Sidow. At the time he was President & Chief Executive Officer for Moximed and had been since 2008.Prior to his time at Moximed, Kevin was President & CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.Here are a few of the things we learned from Kevin:- How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.- What makes the Atlas System different than other orthopedic knee implants?- How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.See more...

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.